Following on from information provided to NICE by the company in July 2020 the appraisal of Lung disease (interstitial, systemic sclerosis) - nintedanib (Boehringer Ingleheim) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1420 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2020 the appraisal of Lung disease (interstitial, systemic sclerosis) - nintedanib (Boehringer Ingleheim) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 September 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. For information and following advice received from the company, the appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease [ID1420] has now been suspended. This is because the Scleroderma-associated interstitial lung disease (SSc-ILD) population for ID1420 will now be covered within the licence for the appraisal for nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]. For further information on the timelines for ID1599 please see the following link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10520 |
| 01 September 2020 | Suspended. Topic is suspended |
| 01 September 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. For information and following advice received from the company, the appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease [ID1420] has now been suspended. This is because the Scleroderma-associated interstitial lung disease (SSc-ILD) population for ID1420 will now be covered within the licence for the appraisal for nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]. For further information on the timelines for ID1599 please see the following link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10520 |
| 20 June 2019 | In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nintedanib for treating systemic sclerosis associated with interstitial lung disease. Please note that following on from advice received from the company, information regarding the timelines for this appraisal will be available in due course. |
| 11 January 2019 (14:30) | Scoping workshop (London) |
| 15 November 2018 - 13 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual